Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE:002099)
China · Delayed Price · Currency is CNY 6.92
+0.11 (1.62%)
Feb 3, 2026, 3:04 PM CST
SHE:002099 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,844 | 1,922 | 2,163 | 2,698 | 2,477 | 2,467 |
Other Revenue | 16.43 | 16.43 | 9.14 | 6.39 | 7.99 | 4.88 |
| 1,861 | 1,938 | 2,172 | 2,704 | 2,485 | 2,471 | |
Revenue Growth (YoY) | -4.08% | -10.75% | -19.68% | 8.83% | 0.54% | -15.98% |
Cost of Revenue | 1,557 | 1,595 | 1,983 | 2,024 | 1,602 | 1,428 |
Gross Profit | 303.87 | 343.72 | 189.17 | 680.2 | 882.35 | 1,043 |
Selling, General & Admin | 316.34 | 329.6 | 345.07 | 407.92 | 563.71 | 462.86 |
Research & Development | 121.35 | 129.45 | 115.56 | 144.91 | 164.64 | 131.98 |
Other Operating Expenses | 16.56 | 11.67 | 9.43 | 11.71 | 26.73 | 24.18 |
Operating Expenses | 464.26 | 475.26 | 456.65 | 582.06 | 765.17 | 621.25 |
Operating Income | -160.39 | -131.53 | -267.47 | 98.14 | 117.18 | 422.05 |
Interest Expense | -26.42 | -28.8 | -37.76 | -36.55 | -21.89 | -11.36 |
Interest & Investment Income | 63 | 64.63 | 68.13 | 33.47 | 36.34 | 30.87 |
Currency Exchange Gain (Loss) | 35.03 | 35.03 | 2.81 | 107.95 | -30.28 | -53 |
Other Non Operating Income (Expenses) | -22.26 | -2.02 | -1.85 | -2.4 | -1.03 | -0.9 |
EBT Excluding Unusual Items | -111.04 | -62.68 | -236.15 | 200.62 | 100.31 | 387.66 |
Impairment of Goodwill | -208.47 | -208.47 | -107.69 | -46.73 | - | - |
Gain (Loss) on Sale of Investments | -35.96 | -35.24 | -117.62 | -45.68 | 6.46 | -20.31 |
Gain (Loss) on Sale of Assets | 0.48 | 1.04 | 12.88 | 0.29 | -1.48 | 0.34 |
Asset Writedown | 30.76 | -34.38 | -25.13 | -13.42 | 0.55 | -0.99 |
Other Unusual Items | 2.86 | 2.86 | 7.5 | 5.73 | 17.18 | 26.8 |
Pretax Income | -321.38 | -336.88 | -466.22 | 100.8 | 123.03 | 393.51 |
Income Tax Expense | 17.7 | -2.99 | -44.64 | 14.73 | 29.17 | 73.81 |
Earnings From Continuing Operations | -339.08 | -333.89 | -421.58 | 86.08 | 93.87 | 319.7 |
Minority Interest in Earnings | 4.13 | 3.62 | 1.53 | 1.94 | 1.36 | 0.02 |
Net Income | -334.96 | -330.27 | -420.06 | 88.01 | 95.23 | 319.72 |
Net Income to Common | -334.96 | -330.27 | -420.06 | 88.01 | 95.23 | 319.72 |
Net Income Growth | - | - | - | -7.58% | -70.21% | -58.52% |
Shares Outstanding (Basic) | 1,583 | 1,573 | 1,616 | 1,760 | 1,587 | 1,599 |
Shares Outstanding (Diluted) | 1,583 | 1,573 | 1,616 | 1,760 | 1,587 | 1,599 |
Shares Change (YoY) | 48.34% | -2.66% | -8.22% | 10.91% | -0.71% | -0.45% |
EPS (Basic) | -0.21 | -0.21 | -0.26 | 0.05 | 0.06 | 0.20 |
EPS (Diluted) | -0.21 | -0.21 | -0.26 | 0.05 | 0.06 | 0.20 |
EPS Growth | - | - | - | -16.67% | -70.00% | -58.33% |
Free Cash Flow | -46.43 | 52.73 | 87.46 | -63.33 | -127.2 | 459.69 |
Free Cash Flow Per Share | -0.03 | 0.03 | 0.05 | -0.04 | -0.08 | 0.29 |
Dividend Per Share | - | - | - | 0.050 | 0.100 | 0.020 |
Dividend Growth | - | - | - | -50.00% | 400.00% | -93.33% |
Gross Margin | 16.33% | 17.73% | 8.71% | 25.15% | 35.51% | 42.22% |
Operating Margin | -8.62% | -6.78% | -12.31% | 3.63% | 4.72% | 17.08% |
Profit Margin | -18.00% | -17.04% | -19.34% | 3.26% | 3.83% | 12.94% |
Free Cash Flow Margin | -2.50% | 2.72% | 4.03% | -2.34% | -5.12% | 18.60% |
EBITDA | 160.99 | 206.48 | 92.7 | 429.78 | 406.32 | 678.62 |
EBITDA Margin | 8.65% | 10.65% | 4.27% | 15.89% | 16.35% | 27.46% |
D&A For EBITDA | 321.39 | 338.01 | 360.17 | 331.64 | 289.14 | 256.57 |
EBIT | -160.39 | -131.53 | -267.47 | 98.14 | 117.18 | 422.05 |
EBIT Margin | -8.62% | -6.78% | -12.31% | 3.63% | 4.72% | 17.08% |
Effective Tax Rate | - | - | - | 14.61% | 23.71% | 18.76% |
Revenue as Reported | 1,861 | 1,938 | 2,172 | 2,704 | 2,485 | 2,471 |
Advertising Expenses | - | 2.99 | 2.79 | 0.21 | 0.64 | 1.77 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.